In potential good news for Prothena, Roche announced earlier this week that it will advance Prothena-partnered prasinezumab into phase 3 trials for early-stage Parkinson’s disease, despite the ...

June 18, 2025 — 07:42 am EDT Written by None for Quiver Quantitative -> Biogen launches Phase 3 BRAVE study to assess omaveloxolone's effects in children with Friedreich ataxia. Quiver AI Summary ...

The Soo Locks SAULT STE. MARIE, Mich. — U.S. Army Corps of Engineers, Detroit District’s New Lock at the Soo project in Sault Ste. Marie, Michigan, awards a total of $95.3 million for remaining Phase ...

PETACH TIKVA, Israel, June 17, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (" PolyPid ” or the " Company ”), a late-stage biopharma company aiming to improve surgical outcomes, today ...

The Montreal Protocol The Montreal Protocol on Substances that Deplete the Ozone Layer is the landmark multilateral environmental agreement that regulates the production and consumption of nearly 100 ...

Bagsværd, Denmark, 12 June 2025 – Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical ...

RAHWAY, N.J., June 12, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 Phase 3 clinical trial evaluating the safety ...

A 60-GHz digitally controlled phase-inverting variable gain amplifier (PIVGA) is presented, with a gain control range from -9.4 to 6 dB, and a 180° phase inversion. Four digitally controlled nMOS ...

With what Insmed calls an "outstanding" phase 2 win for its treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH), the company is racing to phase 3 a ...

JERUSALEM — Israel and Germany have started preparations to deliver the the Arrow-3 missile shield to German forces in the coming months, the Israeli Ministry of Defense announced. According to ...

Otsuka Pharmaceutical has shared more detailed data behind its kidney disease drug’s phase 3 win, showing the monoclonal antibody halved patients’ urine protein-to-creatinine ratio (UPCR) levels.